Intra-arterial vasodilators infusion for management of reversible cerebral vasoconstriction syndrome in a 12-year-old girl: A case report.
case report
children
headache
pediatric intensive care unit
reversible cerebral vasoconstriction syndrome
vessel wall MRI
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2022
accepted:
30
01
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Reversible cerebral vasoconstriction syndrome (RCVS) is a vascular disease characterized by diffuse transient vasoconstriction and vasodilatation of the cerebral arteries. It is commonly associated with recurrent severe acute headaches with or without focal neurological deficits due to hemorrhages, infarcts, and even posterior reversible encephalopathy syndrome. The optimal management of acute neurologic deficits caused by RCVS is still uncertain. Calcium channel blockers (CCBs) such as nimodipine or verapamil have been reported to be effective in adult series. Intra-arterial injection of nimodipine, verapamil, and milrinone has recently been demonstrated to be safe and effective for treating severe segmental vasoconstriction in adults. CCBs are the most used treatment in the available pediatric literature. Intra-arterial vasodilators have been reported in some rare pediatric reports with more severe diseases, but their utility is still under investigation. We report a case of a 12-year-old girl who underwent a severe course of RCVS complicated by multiple cerebral infarcts, treated by several sessions of intra-arterial vasodilators infusion.
Identifiants
pubmed: 36937972
doi: 10.3389/fped.2023.1042509
pmc: PMC10020348
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1042509Informations de copyright
© 2023 Rizzati, Marie, Chanez, Ferry, Natterer, Longchamp, Saliou and Perez.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):E184-7
pubmed: 21273351
Stroke. 2017 Nov;48(11):3026-3033
pubmed: 29030476
Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1417-21
pubmed: 20936928
Ann Intern Med. 2007 Jan 2;146(1):34-44
pubmed: 17200220
Neurology. 2017 Jan 17;88(3):228-236
pubmed: 27940651
Pediatr Neurol. 2022 Apr;129:1-6
pubmed: 35124533
Dev Med Child Neurol. 2013 Apr;55(4):385-9
pubmed: 23066702
AJNR Am J Neuroradiol. 2014 Aug;35(8):1527-32
pubmed: 24722305
Clin Radiol. 2020 Oct;75(10):730-739
pubmed: 32197916
Stroke. 2010 Nov;41(11):2505-11
pubmed: 20884871
Headache. 2009 Jan;49(1):142-5
pubmed: 18647181
Semin Pediatr Neurol. 2021 Dec;40:100936
pubmed: 34749919
J Child Neurol. 2017 Jun;32(7):614-623
pubmed: 28511631
Lancet Neurol. 2012 Oct;11(10):906-17
pubmed: 22995694
Arch Neurol. 2011 Aug;68(8):1005-12
pubmed: 21482916
Neurology. 2017 Jan 17;88(3):224-225
pubmed: 27940649
Stroke. 2012 Mar;43(3):860-2
pubmed: 22156692